Literature DB >> 25492994

Microbiota and the gut-liver axis: bacterial translocation, inflammation and infection in cirrhosis.

Valerio Giannelli1, Vincenza Di Gregorio1, Valerio Iebba1, Michela Giusto1, Serena Schippa1, Manuela Merli1, Ulrich Thalheimer1.   

Abstract

Liver disease is associated with qualitative and quantitative changes in the intestinal microbiota. In cirrhotic patients the alteration in gut microbiota is characterized by an overgrowth of potentially pathogenic bacteria (i.e., gram negative species) and a decrease in autochthonous familiae. Here we summarize the available literature on the risk of gut dysbiosis in liver cirrhosis and its clinical consequences. We therefore described the features of the complex interaction between gut microbiota and cirrhotic host, the so called "gut-liver axis", with a particular attention to the acquired risk of bacterial translocation, systemic inflammation and the relationship with systemic infections in the cirrhotic patient. Such knowledge might help to develop novel and innovative strategies for the prevention and therapy of gut dysbiosis and its complication in liver cirrhosis.

Entities:  

Keywords:  Bacterial overgrowth; Bacterial translocation; Cirrhosis; Dysbiosis; Gut; Infection; Inflammation; Lactulose; Liver; Portal hypertension; Rifaximine

Mesh:

Year:  2014        PMID: 25492994      PMCID: PMC4258550          DOI: 10.3748/wjg.v20.i45.16795

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  106 in total

Review 1.  The interaction between bacteria and bile.

Authors:  Máire Begley; Cormac G M Gahan; Colin Hill
Journal:  FEMS Microbiol Rev       Date:  2005-09       Impact factor: 16.408

Review 2.  Pathological bacterial translocation in liver cirrhosis.

Authors:  Reiner Wiest; Melissa Lawson; Markus Geuking
Journal:  J Hepatol       Date:  2013-08-28       Impact factor: 25.083

3.  Effect of lactitol and lactulose administration on the fecal flora in cirrhotic patients.

Authors:  O Riggio; M Varriale; G P Testore; R Di Rosa; E Di Rosa; M Merli; A Romiti; C Candiani; L Capocaccia
Journal:  J Clin Gastroenterol       Date:  1990-08       Impact factor: 3.062

4.  Effects of the adjunctive probiotic VSL#3 on portal haemodynamics in patients with cirrhosis and large varices: a randomized trial.

Authors:  Nitin Gupta; Ashish Kumar; Praveen Sharma; Vishal Garg; Barjesh C Sharma; Shiv K Sarin
Journal:  Liver Int       Date:  2013-04-21       Impact factor: 5.828

5.  Altered intestinal function precedes the appearance of bacterial DNA in serum and ascites in patients with cirrhosis: a pilot study.

Authors:  Ulrich Thalheimer; Fosca De Iorio; Franco Capra; Maria del Mar Lleo; Valeria Zuliani; Valentina Ghidini; Maria Carla Tafi; Greta Caburlotto; Micol Gennari; Andrew K Burroughs; Italo Vantini
Journal:  Eur J Gastroenterol Hepatol       Date:  2010-10       Impact factor: 2.566

6.  TLR4 enhances TGF-beta signaling and hepatic fibrosis.

Authors:  Ekihiro Seki; Samuele De Minicis; Christoph H Osterreicher; Johannes Kluwe; Yosuke Osawa; David A Brenner; Robert F Schwabe
Journal:  Nat Med       Date:  2007-10-21       Impact factor: 53.440

Review 7.  Use and abuse of hydrogen breath tests.

Authors:  M Simrén; P-O Stotzer
Journal:  Gut       Date:  2006-03       Impact factor: 23.059

Review 8.  Pathogenic Escherichia coli.

Authors:  James B Kaper; James P Nataro; Harry L Mobley
Journal:  Nat Rev Microbiol       Date:  2004-02       Impact factor: 60.633

9.  Current views of toll-like receptor signaling pathways.

Authors:  Masahiro Yamamoto; Kiyoshi Takeda
Journal:  Gastroenterol Res Pract       Date:  2010-12-14       Impact factor: 2.260

10.  Modulation of the metabiome by rifaximin in patients with cirrhosis and minimal hepatic encephalopathy.

Authors:  Jasmohan S Bajaj; Douglas M Heuman; Arun J Sanyal; Phillip B Hylemon; Richard K Sterling; R Todd Stravitz; Michael Fuchs; Jason M Ridlon; Kalyani Daita; Pamela Monteith; Nicole A Noble; Melanie B White; Andmorgan Fisher; Masoumeh Sikaroodi; Huzefa Rangwala; Patrick M Gillevet
Journal:  PLoS One       Date:  2013-04-02       Impact factor: 3.240

View more
  64 in total

1.  Is small intestinal bacterial overgrowth a cause of hyperdynamic circulation in cirrhosis?

Authors:  Roman Maslennikov; Chavdar Pavlov; Vladimir Ivashkin
Journal:  Turk J Gastroenterol       Date:  2019-11       Impact factor: 1.852

Review 2.  The dormant blood microbiome in chronic, inflammatory diseases.

Authors:  Marnie Potgieter; Janette Bester; Douglas B Kell; Etheresia Pretorius
Journal:  FEMS Microbiol Rev       Date:  2015-05-03       Impact factor: 16.408

3.  Pediatric Fatty Liver Disease.

Authors:  Ajay Jain
Journal:  Mo Med       Date:  2019 Mar-Apr

Review 4.  The role of the gastrointestinal tract and microbiota on uremic toxins and chronic kidney disease development.

Authors:  David Briskey; Patrick Tucker; David W Johnson; Jeff S Coombes
Journal:  Clin Exp Nephrol       Date:  2016-03-10       Impact factor: 2.801

5.  Small intestinal bacterial overgrowth in cirrhosis: systematic review and meta-analysis.

Authors:  Roman Maslennikov; Chavdar Pavlov; Vladimir Ivashkin
Journal:  Hepatol Int       Date:  2018-10-04       Impact factor: 6.047

6.  Preserved Gut Microbial Diversity Accompanies Upregulation of TGR5 and Hepatobiliary Transporters in Bile Acid-Treated Animals Receiving Parenteral Nutrition.

Authors:  Ajay Kumar Jain; Abhineet Sharma; Sumit Arora; Keith Blomenkamp; Ik Chan Jun; Robert Luong; David John Westrich; Aayush Mittal; Paula M Buchanan; Miguel A Guzman; John Long; Brent A Neuschwander-Tetri; Jeffery Teckman
Journal:  JPEN J Parenter Enteral Nutr       Date:  2016-08-20       Impact factor: 4.016

Review 7.  What is new about diet in hepatic encephalopathy.

Authors:  Manuela Merli; Valerio Iebba; Michela Giusto
Journal:  Metab Brain Dis       Date:  2015-09-29       Impact factor: 3.584

8.  Role of systemic inflammation in cirrhosis: From pathogenesis to prognosis.

Authors:  Melisa Dirchwolf; Andrés Eduardo Ruf
Journal:  World J Hepatol       Date:  2015-08-08

Review 9.  Effect of rifaximin on gut microbiota composition in advanced liver disease and its complications.

Authors:  Francesca Romana Ponziani; Viviana Gerardi; Silvia Pecere; Francesca D'Aversa; Loris Lopetuso; Maria Assunta Zocco; Maurizio Pompili; Antonio Gasbarrini
Journal:  World J Gastroenterol       Date:  2015-11-21       Impact factor: 5.742

Review 10.  Gut epithelial barrier dysfunction in human immunodeficiency virus-hepatitis C virus coinfected patients: Influence on innate and acquired immunity.

Authors:  Mercedes Márquez; Clotilde Fernández Gutiérrez del Álamo; José Antonio Girón-González
Journal:  World J Gastroenterol       Date:  2016-01-28       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.